Endpoint surrogacy in oncology Phase 3 randomised controlled trials.
| dc.contributor.author | Zhang, Jianrong | |
| dc.contributor.author | Pilar, Meagan R | |
| dc.contributor.author | Wang, Xiaofei | |
| dc.contributor.author | Liu, Jingxia | |
| dc.contributor.author | Pang, Herbert | |
| dc.contributor.author | Brownson, Ross C | |
| dc.contributor.author | Colditz, Graham A | |
| dc.contributor.author | Liang, Wenhua | |
| dc.contributor.author | He, Jianxing | |
| dc.date.accessioned | 2024-03-31T17:35:43Z | |
| dc.date.available | 2024-03-31T17:35:43Z | |
| dc.date.issued | 2020-08 | |
| dc.description.abstract | Endpoint surrogacy is an important concept in oncology trials. Using a surrogate endpoint like progression-free survival as the primary endpoint-instead of overall survival-would lead to a potential faster drug approval and therefore more cancer patients with an earlier opportunity to receive the newly approved drugs. | |
| dc.identifier | 10.1038/s41416-020-0896-5 | |
| dc.identifier.issn | 0007-0920 | |
| dc.identifier.issn | 1532-1827 | |
| dc.identifier.uri | ||
| dc.language | eng | |
| dc.publisher | Springer Science and Business Media LLC | |
| dc.relation.ispartof | British journal of cancer | |
| dc.relation.isversionof | 10.1038/s41416-020-0896-5 | |
| dc.rights.uri | ||
| dc.subject | Humans | |
| dc.subject | Neoplasms | |
| dc.subject | Drug Approval | |
| dc.subject | Biomarkers | |
| dc.subject | Progression-Free Survival | |
| dc.title | Endpoint surrogacy in oncology Phase 3 randomised controlled trials. | |
| dc.type | Journal article | |
| duke.contributor.orcid | Wang, Xiaofei|0000-0001-7512-8445 | |
| pubs.begin-page | 333 | |
| pubs.end-page | 334 | |
| pubs.issue | 3 | |
| pubs.organisational-group | Duke | |
| pubs.organisational-group | School of Medicine | |
| pubs.organisational-group | Basic Science Departments | |
| pubs.organisational-group | Institutes and Centers | |
| pubs.organisational-group | Biostatistics & Bioinformatics | |
| pubs.organisational-group | Duke Cancer Institute | |
| pubs.organisational-group | Biostatistics & Bioinformatics, Division of Biostatistics | |
| pubs.publication-status | Published | |
| pubs.volume | 123 |
Files
Original bundle
- Name:
- Endpoint surrogacy in oncology Phase 3 randomised controlled trials.pdf
- Size:
- 236.4 KB
- Format:
- Adobe Portable Document Format
- Description:
- Published version